Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Board of Directors
        • Joerg Reinhardt
        • Simon Moroney
        • Nancy Andrews
        • Ton Buechner
        • Patrice Bula
        • Elizabeth Doherty
        • Ana de Pro Gonzalo
        • Bridgette Heller
        • Daniel Hochstrasser
        • Frans van Houten
        • Andreas von Planta
        • Charles Sawyers
        • William Winters
        • Charlotte Pamer-Wieser
      • Executive Committee
        • Vasant Narasimhan
        • Shreeram Aradhye
        • James Bradner
        • Victor Bulto
        • Aharon (Ronny) Gal
        • Karen Hale
        • Harry Kirsch
        • Rob Kowalski
        • Steffen Lang
        • Klaus Moosmayer
        • Richard Saynor
        • Marie-France Tschudin
        • Lutz Hegemann
        • Michael Willi
        • Kees Roks
      • Strategy
        • People and Culture
        • Data and Digital
      • Products
      • Innovative Medicines
      • Sandoz
      • Diversity & Inclusion
        • Equity
        • Diversity & Inclusion Governance and Community
        • Inclusivity
        • Parental Leave
        • Society
      • Manufacturing
      • Quality
        • Audit program
        • Novartis Quality Management System (QMS)
        • Product and patient safety training
        • Regulatory inspections
        • Product recalls
        • Third-party suppliers
      About Novartis
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient Organization Funding
      • Adverse Event Reporting
      • COVID-19: Patients and Caregivers
      • Stories: Patients Perspectives
      Patients & Caregivers
    • Healthcare Professionals
      • Medical Congresses and Events
        • Abstract summaries for EULAR
        • Abstract summaries for ACR
        • Abstract summaries for EADV
      • Products
      • Novartis Pipeline
      • Managed Access Programs
        • Novartis Gene Therapies Managed Access Program
      • Novartis External Funding
      • Healthcare Professional Resources by Country
      • Investigator-Initiated Trials / Studies
      • Transparency and Disclosure
      • Novartis Medical Information
        • Submit medical enquiry
      Healthcare Professionals
    • Research & Development
      • Novartis Institutes for BioMedical Research
        • Collaborations
        • NIBR Global Scholars Program
      • Technology Platforms
        • Radioligand Therapy
        • Gene Therapy
        • Cell Therapy
      • Research Disease Areas
        • Immuno-oncology research at Novartis
        • Oncology research at Novartis
        • Cardiovascular and metabolic disease research at Novartis
        • Autoimmunity, transplantation and inflammatory disease research at Novartis
        • Ophthalmology research at Novartis
        • Neuroscience Research at Novartis
        • Musculoskeletal Disease Research at Novartis
        • DAx: exploratory disease research at Novartis
      • Research Locations
        • Novartis Institute for Tropical Diseases
      • Novartis Pipeline
      • Translational Medicine
      • Research & Development Approach
      • Research Collaborations
      • Open Source Science
      • Stories from our Labs
      Research & Development
    • ESG
      • Access
        • Creating sustainable business models
        • Value-Based Pricing
        • Sub-Saharan Africa
        • Donations
        • Novartis Access Principles
        • Novartis Oncology Access
        • Patents and Licensing
      • Ethics, Risk and Compliance
        • Ethical Behavior
        • Compliance
        • Human Rights
        • Learning and Engagement
        • Risk management
      • Environmental Sustainability
        • Climate
        • Waste
        • Water
      • Global Health
        • Anti-Microbial Resistance (AMR)
        • Avoidable Blindness
        • Chagas Disease
        • Leprosy
        • Malaria
        • Sickle Cell Disease (SCD)
        • Novartis Foundation
      • Diversity & Inclusion
      • Reporting
        • ESG Rating Performance
        • Codes, Policies and Guidelines
        • Materiality Assessment
        • Transparency and Disclosure
        • Targets
        • Positions
      • ESG Index
      Environmental, Social and Governance
    • Investors
      • Event Calendar
      • Financial Data
        • Novartis Annual Results
        • Novartis Quarterly Results
        • Novartis SEC Filings
        • Product Sales
        • Fixed-Income Securities
        • Expected Currency Impact
      • Share Data & Analysis
        • Share Monitor
        • Dividend Information
        • Share Ownership
        • Share Overview
      • Shareholder Information
        • General Meetings
        • American Depository Receipts (ADR)
        • Share Buy-Back
        • Frequently Asked Questions
      • Company Overview
        • Corporate Governance
      • Novartis Annual Reporting Suite
        • Reporting Archive
        • Publications Order Form
      • ESG
      Investors
    • News
      • News Archive
      • Media Library
      • Stories
      • Subscribe
      News
    • Careers
      • Career Search
      • Our Teams
        • Careers in Commercial
        • Careers in Communications and Advocacy
        • Careers in Consulting
        • Careers in Digital
        • Careers in Health, Safety & Environment
        • Careers in Information Technology (IT)
        • Careers in Medical & Development
        • Careers in People & Organization
        • Careers in Procurement
        • Careers in Research
        • Careers in Strategy
        • Careers in Manufacturing and Supply
        • Ethics, Risk & Compliance (ERC)
        • Careers in Legal
      • Career Programs
        • Community Exploration & Learning Lab (CELL)
      • Early Talent
      • Postdoc Program
        • Andreas Bender, PhD
        • Boxun Lu, PhD
        • The Novartis Innovation Postdoctoral Fellowship
        • The Novartis Discovery Postdoctoral Fellowship
        • Postdoc Research Themes
        • Recognition
        • Postdoc Program Leadership
      • International Careers
      • Learning and Development
      • Well-being
      • Internship Programs
      Careers
    • COVID-19 Information Center
      COVID-19 Novartis response
    • Clinical Trials
      Clinical Trials
    • Partnering
      Partnering
    • Contacts
      Contacts
    Home
  • Discovery
    A shared mission to take on the “impossible” in cancer research
    CancerDrug DiscoveryNovartis Institutes for BioMedical ResearchOncologyWomen in Science
  • Discovery
    How Emily’s act of bravery inspired a wave of continued innovation

    Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.

    CancerCell and Gene TherapyChildren's HealthNovartis Institutes for BioMedical ResearchOncology
  • Access to Healthcare
    Tackling the health toll of climate change
    Chronic IllnessEnvironmental SustainabilityInfectious DiseasesMalariaNovartis Institutes for BioMedical Research
  • Discovery
    Stopping this coronavirus – and the next one

    Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.

    Biomedical ResearchCOVID-19Drug DiscoveryNovartis Institutes for BioMedical ResearchScientific Research
  • Discovery
    On being and becoming a data science company

    A conversation with Novartis Chief Digital Officer Bertrand Bodson

    InnovationNovartis Institutes for BioMedical ResearchWorking at Novartis
  • From Our Labs
    Why Novartis scouts for disruptive technology

    Cambridge neighbors, NIBR and Harvard, further disrupt technology. Read how their alliance is accelerating drug discovery.

    Novartis Institutes for BioMedical Research
  • From Our Labs
    Seeing through knees in quest to alleviate osteoarthritis

    Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.

    InnovationNovartis Institutes for BioMedical ResearchScientific Research
  • From Our Labs
    How a 19th-century technology is speeding up drug discovery

    Pneumatic tube systems have existed for 150+ years and have transported everything from telegrams to aircraft parts. Now they’re being used in our labs.

    Emerging TechnologyInnovationNovartis Institutes for BioMedical Research
  • From Our Labs
    Advancing medicine through collaboration

    In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.

    Drug DiscoveryEmerging TechnologyInnovationNovartis Institutes for BioMedical ResearchPostdoc Program
  • Discovery
    Visualizing molecular glues

    Molecular glues are a new type of medicine inspired by nature’s matchmakers.

    Drug DesignInnovationNovartis Institutes for BioMedical ResearchScientific Research
  • Discovery
    Using Super-Resolution Microscopy To See Neurodegeneration

    Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.

    Neurodegenerative DiseaseNeuroscienceNovartis Institutes for BioMedical ResearchScientific ResearchAlzheimer’s disease
  • Discovery
    Toward improving the health and longevity of transplanted organs

    Novartis researchers are working to extend the life of organ transplants

    InnovationMedical InnovationsNovartis Institutes for BioMedical ResearchClinical ResearchClinical Trials

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience